SecBot SecBot
8-K ·Filed Apr 6, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed7mo ago SEC0001193125-26-142885
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

Traders should anticipate continued share price pressure due to the significant dilution from this offering. Monitor the company's cash runway and progress toward FDA approval for INO-3107, as these will be key factors in determining whether the capital raise provides sufficient runway to achieve value inflection points or merely delays potential insolvency.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.13
T+0 close · Apr 6, 2026 · via day close
Latest settled
+5.31%
T+60 · $1.19
Vs SPY
−8.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $1.13entry
  2. T+1 · 7mo ago −7.08%α −7.14% · $1.05
  3. T+5 · 7mo ago −3.54%α −7.67% · $1.09
  4. T+20 · 7mo ago +0.89%α −8.10% · $1.14
  5. T+60 · 5mo ago +5.31%α −8.16% · $1.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals entered into a material definitive agreement (Item 1.01) to conduct a public offering of 12.5 million shares of common stock and accompanying warrants, raising approximately $16.45 million in gross proceeds before expenses. This offering, combined with a recent capital raise, indicates the company is securing funds amid ongoing uncertainty about its ability to continue as a going concern, leading to significant shareholder dilution.

Key Financial Metrics

Deal Value
$17.5M

Key Facts

  • Inovio Pharmaceuticals is conducting a public offering of 12,500,000 shares of common stock, Series A warrants to purchase up to 12,500,000 shares, and Series B warrants to purchase up to 12,500,000 shares.
  • The combined public offering price is $1.40 per share and accompanying warrants, with gross proceeds of $17.5 million and net proceeds of approximately $16.45 million after underwriting discounts.
  • The offering includes an over-allotment option for up to an additional 1,875,000 shares and warrants.
  • This capital raise follows a recent 424B5 filing, indicating a pattern of dilutive financing to fund operations.
  • The company has acknowledged substantial doubt about its ability to continue as a going concern.

Financial Impact

Raises $16.45 million in net proceeds through issuance of 12.5 million common shares and 25 million warrants, causing immediate and significant shareholder dilution.

dilutioncashequity

Risk Factors

  • Substantial shareholder dilution from the issuance of new shares and warrants
  • Ongoing uncertainty about the company's ability to continue as a going concern
  • Risk that the raised capital will not be sufficient to achieve commercial milestones or secure additional funding

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142885
Document: d137120dex42.htm0001193125-26-142885
Document: d137120dex43.htm0001193125-26-142885
Document: d137120dex41.htm0001193125-26-142885

Track record

20 reports on INO

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026